{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:07:17Z","timestamp":1762542437215,"version":"build-2065373602"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The use of direct oral anticoagulants, such as rivaroxaban, is preferred over vitamin K antagonists. Several clinical scenarios highlighting potential benefits of measuring plasma concentrations have been reported. This study aimed to describe the clinical experience with rivaroxaban in adult patients and develop a mathematical model to predict rivaroxaban concentrations using routine coagulation screening assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were prospectively collected over a 4-year-period, including clinical patient characteristics, total plasma rivaroxaban concentrations, and screening coagulation assays, if available. Prothrombin time, activated partial thromboplastin time (aPTT), and thrombin clotting time were included in the model to predict rivaroxaban concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There were 403 rivaroxaban concentrations with a median of 66 mcg\/L. The most common indications for measuring rivaroxaban concentration were routine postinitiation (78\/403, 19%), breakthrough thromboembolic or bleeding events (98\/403, 24%), and post-dose adjustments (42\/403, 10%). Dose adjustments were made after measuring rivaroxaban concentrations in 85 patients (85\/403, 21%). A statistically significant relationship existed between PT and aPTT against rivaroxaban concentrations; however, attempts to construct an accurate mathematical model using linear regression to determine rivaroxaban concentrations based on these coagulation assays were unsuccessful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>There was a wide range of measured rivaroxaban concentrations, reflecting the diversity of indications for measurement, with a significant minority associated with subsequent changes in rivaroxaban dosing. Given the frequency of altering dosing regimens based on the results, future efforts should focus on the correlation of concentration data with clinical endpoints to determine reference ranges. An accurate mathematical model to determine rivaroxaban concentrations based on coagulation screening assays could not be developed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001361","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:00:27Z","timestamp":1752667227000},"page":"e150-e156","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Rivaroxaban Plasma Concentrations Cannot be Predicted from Coagulation Assays: Real-Life Experience From a Tertiary Hospital in New Zealand"],"prefix":"10.1097","volume":"47","author":[{"given":"Yassar","family":"Alamri","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand;"},{"name":"Department of Medicine, University of Otago, Christchurch, New Zealand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Sundermann","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago, Christchurch, New Zealand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"O'Mahony","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Hiskett","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago, Christchurch, New Zealand;"},{"name":"Toxicology, Department of Specialist Biochemistry, Canterbury Health Laboratories, Christchurch, New Zealand; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Neal","sequence":"additional","affiliation":[{"name":"Department of Haematology, Christchurch Hospital, Christchurch, New Zealand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand;"},{"name":"Department of Medicine, University of Otago, Christchurch, New Zealand;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"R1-20251107","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart association Joint Committee on clinical practice guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"R2-20251107","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","article-title":"Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012-2021","volume":"Aug;166","author":"Stevens","year":"2024","journal-title":"Chest"},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0035-1546465","article-title":"Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants?","volume":"41","author":"Chin","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.thromres.2021.08.010","article-title":"A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: the Retro-AOD study","volume":"206","author":"Cavaillez","year":"2021","journal-title":"Thromb Res"},{"issue":"6","key":"R5-20251107","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/imj.16329","article-title":"Retrospective study of clinical settings, indications and consequences of measurement of direct oral anticoagulant plasma levels in Northern Tasmania, Australia","volume":"Jun;54","author":"Lim","year":"2024","journal-title":"Intern Med J"},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2016.04.019","article-title":"Direct oral anticoagulant drug level testing in clinical practice: a single institution experience","volume":"143","author":"Martin","year":"2016","journal-title":"Thromb Res"},{"key":"R7-20251107","article-title":"Variation in plasma levels of apixaban and rivaroxaban in clinical routine treatment of venous thromboembolism","volume":"12","author":"Reda","year":"2022","journal-title":"Life (Basel, Switzerland)"},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.thromres.2021.01.021","article-title":"Direct oral anticoagulant plasma level measurement in clinical practice: a French single-institution retrospective study","volume":"200","author":"Car\u00e9","year":"2021","journal-title":"Thromb Res"},{"key":"R9-20251107","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11239-018-1643-0","article-title":"Direct-acting oral anticoagulant drug level monitoring in clinical patient management","volume":"45","author":"Rottenstreich","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2019.01.016","article-title":"Clinical impact of direct oral anticoagulant measuring in a real-life setting","volume":"175","author":"Winther-Larsen","year":"2019","journal-title":"Thromb Res"},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tru.2021.100049","article-title":"Direct oral anticoagulant blood level monitoring in daily practice","volume":"3","author":"Bavalia","year":"2021","journal-title":"Thromb Update"},{"key":"R12-20251107","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/FTD.0000000000000713","article-title":"Routine therapeutic drug monitoring of dabigatran: experience at a tertiary center","volume":"42","author":"Chin","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/FTD.0000000000000744","article-title":"Simultaneous determination of dabigatran, rivaroxaban, and apixaban in human plasma by liquid chromatography\/tandem mass spectrometry","volume":"42","author":"Zhang","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R14-20251107","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thromb Res"},{"key":"R15-20251107","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/ijlh.12944","article-title":"A level-headed approach to measuring direct oral anticoagulants: a 2-year retrospective analysis of DOAC levels from a tertiary UK centre","volume":"41","author":"Denny","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"suppl 1","key":"R16-20251107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/ijlh.12654","article-title":"Laboratory measurement of the direct oral anticoagulants: indications and impact on management in clinical practice","volume":"39","author":"Wright","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"R17-20251107","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/FTD.0000000000001034","article-title":"TDM is alive and kicking","volume":"45","author":"Lemaitre","year":"2023","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:00:28Z","timestamp":1762542028000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001361","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"2024-12-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}